Mount Christopher W, Gonzalez Castro Luis Nicolas
Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Antibodies (Basel). 2022 Apr 27;11(2):31. doi: 10.3390/antib11020031.
Immunotherapy has revolutionized the care of cancer patients. A diverse set of strategies to overcome cancer immunosuppression and enhance the tumor-directed immune response are in clinical use, but have not achieved transformative benefits for brain tumor patients. Adoptive cell therapies, which employ a patient's own immune cells to generate directed anti-tumor activity, are emerging technologies that hold promise to improve the treatment of primary brain tumors in children and adults. Here, we review recent advances in chimeric antigen receptor (CAR) T-cell therapies for the treatment of aggressive primary brain tumors, including glioblastoma and diffuse midline glioma, H3 K27M-mutant. We highlight current approaches, discuss encouraging investigational data, and describe key challenges in the development and implementation of these types of therapies in the neuro-oncology setting.
免疫疗法彻底改变了癌症患者的治疗方式。目前临床上采用了多种克服癌症免疫抑制和增强肿瘤定向免疫反应的策略，但尚未给脑肿瘤患者带来变革性的益处。过继性细胞疗法利用患者自身的免疫细胞产生定向抗肿瘤活性，是有望改善儿童和成人原发性脑肿瘤治疗的新兴技术。在此，我们综述嵌合抗原受体（CAR）T细胞疗法在治疗侵袭性原发性脑肿瘤（包括胶质母细胞瘤和H3 K27M突变的弥漫性中线胶质瘤）方面的最新进展。我们重点介绍了当前的方法，讨论了令人鼓舞的研究数据，并描述了在神经肿瘤学环境中开发和实施这类疗法的关键挑战。
